Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.34USD
9:53pm IST
Change (% chg)

$0.53 (+1.27%)
Prev Close
$41.81
Open
$41.89
Day's High
$42.43
Day's Low
$41.76
Volume
1,498,850
Avg. Vol
8,311,130
52-wk High
$46.46
52-wk Low
$34.32

Latest Key Developments (Source: Significant Developments)

Zenith Epigenetics Gains U.S. FDA Clearance Of Investigational New Drug Application For ZEN-3694 In TNBC Program
Monday, 18 Mar 2019 

March 18 (Reuters) - Pfizer Inc ::ZENITH EPIGENETICS ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ZEN-3694 IN TNBC PROGRAM.ZENITH EPIGENETICS LTD - PFIZER / ZENITH TNBC PROGRAM COLLABORATION ON TARGET TO DOSE FIRST PATIENT IN APRIL 2019.  Full Article

Pfizer's I. Read Receives $19.5 Mln Compensation In 2018
Friday, 15 Mar 2019 

March 14 (Reuters) - Pfizer Inc ::CHAIRMAN & CEO I. READ'S FY 2018 TOTAL COMPENSATION WAS $19.5 MILLION VERSUS $27.9 MILLION IN FY 2017.2018 COMPENSATION OF READ, WHO MOVED FROM HIS ROLE AS CHAIRMAN & CEO TO EXEC CHAIRMAN EFFECTIVE JAN. 1, INCLUDED $7.03 MILLION IN STOCK AWARDS.F. D’AMELIO, CFO'S FY 2018 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $8.3 MILLION IN FY 2017.SAYS A. BOURLA'S FY 2018 TOTAL COMPENSATION AS CHIEF OPERATING OFFICER WAS $9.9 MILLION VERSUS $8.8 MILLION IN FY 2017 - SEC FILING.M. DOLSTEN'S FY 2018 TOTAL COMPENSATION AS PRESIDENT, WORLDWIDE RESEARCH AND DEVELOPMENT WAS $7.1 MILLION VERSUS $7.7 MILLION IN FY 2017.SAYS J. YOUNG'S FY 2018 TOTAL COMPENSATION AS GROUP PRESIDENT, PFIZER INNOVATIVE HEALTH WAS $7.1 MILLION VERSUS $11.5 MILLION IN FY 2017.SAYS THE 2018 ANNUAL TOTAL COMPENSATION FOR READ WAS ABOUT 244 TIMES THE ANNUAL TOTAL COMPENSATION OF THE MEDIAN-PAID EMPLOYEE.2018 COMPENSATION OF READ ALSO INCLUDED $6.9 MILLION IN OPTION AWARDS & $3 MILLION PERFORMANCE-BASED AWARD.SAYS THE ANNUAL 2018 TOTAL COMPENSATION OF THE MEDIAN-PAID EMPLOYEE WAS $80,011.  Full Article

U.S. FDA Approves Pfizer’S Oncology Biosimilar Trazimera
Tuesday, 12 Mar 2019 

March 11 (Reuters) - Pfizer Inc ::U.S. FDA APPROVES PFIZER’S ONCOLOGY BIOSIMILAR TRAZIMERA™ (TRASTUZUMAB-QYYP), A BIOSIMILAR TO HERCEPTIN®1.  Full Article

Pfizer Inc's Drug Trazimera Wins FDA Approval- FDA Website
Tuesday, 12 Mar 2019 

March 11 (Reuters) - Pfizer Inc ::PFIZER INC'S DRUG TRAZIMERA WINS FDA APPROVAL- FDA WEBSITE.  Full Article

New Zealand Commerce Commission Says Received Clearance Application From Glaxosmithkline Seeking Clearance To Buy Consumer Healthcare Business Of Pfizer
Friday, 8 Mar 2019 

March 8 (Reuters) - :NEW ZEALAND COMMERCE COMMISSION - RECEIVED CLEARANCE APPLICATION FROM GLAXOSMITHKLINE SEEKING CLEARANCE TO BUY CONSUMER HEALTHCARE BUSINESS OF PFIZER.  Full Article

Pfizer Prices $5 Billion Debt Offering
Tuesday, 5 Mar 2019 

March 4 (Reuters) - Pfizer Inc ::PFIZER PRICES $5,000,000,000 DEBT OFFERING.PRICING OF A DEBT OFFERING CONSISTING OF $500 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.800% NOTES DUE 2022.ANNOUNCED PRICING OF A DEBT OFFERING CONSISTING OF $750,000,000 AGGREGATE PRINCIPAL AMOUNT OF 2.950% NOTES DUE 2024.PRICING OF A DEBT OFFERING CONSISTING OF $1.75 BILLION AGGREGATE PRINCIPAL AMOUNT OF 3.450% NOTES DUE 2029.ANNOUNCED THE PRICING OF A DEBT OFFERING CONSISTING OF $750,000,000 AGGREGATE PRINCIPAL AMOUNT OF 3.900% NOTES DUE 2039.PRICING OF A DEBT OFFERING CONSISTING OF $1.25 BILLION AGGREGATE PRINCIPAL AMOUNT OF 4.000% NOTES DUE 2049.PFIZER- INTENDS TO USE NET PROCEEDS FOR GENERAL CORPORATE PURPOSES, INCLUDING REFINANCE, REDEEM OR REPURCHASE EXISTING DEBT, TO REPAY PORTION OF ITS OUTSTANDING COMMERCIAL PAPER.  Full Article

Pfizer Files For Potential, 5-Part Notes Offering; Size Not Disclosed
Monday, 4 Mar 2019 

March 4 (Reuters) - Pfizer Inc ::PFIZER INC FILES FOR POTENTIAL, 5-PART NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

BioXcel Therapeutics Announces Addition Of Merck KGaA, Darmstadt, Germany, And Pfizer To Clinical Collaboration With Nektar
Monday, 4 Mar 2019 

March 4 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES ADDITION OF MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER TO CLINICAL COLLABORATION WITH NEKTAR FOR DEVELOPMENT OF TRIPLE-COMBINATION THERAPY IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - BTI WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.BIOXCEL THERAPEUTICS INC - MERCK KGAA, DARMSTADT, GERMANY AND PFIZER SUPPLYING AVELUMAB AND NEKTAR SUPPLYING NKTR-214..BIOXCEL THERAPEUTICS INC - BTI AND NEKTAR WILL EQUALLY SHARE ALL DEVELOPMENT COSTS.  Full Article

Pfizer Receives Positive CHMP Opinion For Lorviqua
Friday, 1 Mar 2019 

March 1 (Reuters) - Pfizer Inc ::PFIZER RECEIVES POSITIVE CHMP OPINION FOR LORVIQUA® (LORLATINIB) FOR CERTAIN ADULT PATIENTS WITH PREVIOUSLY-TREATED ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER.PFIZER INC - CHMP'S OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC), WITH A DECISION EXPECTED IN COMING MONTHS.  Full Article

EU Medicines Agency Recommends Approval Of Pfizer's Vizimpro, Bristol-Myers' Reyataz
Friday, 1 Feb 2019 

Feb 1 (Reuters) - EMA's CHMP::EU MEDICINES AGENCY RECOMMENDATIONS FOR JAN 2019.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER’S LUNG CANCER DRUG VIZIMPRO.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF BRISTOL-MYERS SQUIBB’S HIV DRUG REYATAZ.  Full Article

Photo

FDA approves Pfizer's biosimilar to Roche's Herceptin

The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.